Bone Biologics Corporation
- Jurisdiction
United States - ISIN
US0980706008 (BBLG )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€3.68M - EBIT margin
0.0% - Net income
-€3.62M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts